EDRN Prostate & Urogenital Cancers Collaborative Group Meeting

Friday, April 28, 2023

10:00 a.m. to 1:00 p.m. Eastern Time

Chair: Oliver John Semmes, PhD, Eastern Virginia Medical School

Co-chair: Jeffrey Tosoian, MD, MPH, Vanderbilt University Medical Center

NCI Program Director: Richard Mazurchuk, PhD, National Cancer Institute

Agenda


10:00 a.m. – 10:20 a.m.	Welcome, Introductions, Focus of the Meeting and Updates Oliver John Semmes, PhD, Eastern Virginia Medical School Jeffrey Tosoian, MD, MPH, Vanderbilt University Medical Center Richard Mazurchuk, PhD, National Cancer Institute
10:20 a.m. – 10:40 a.m.	PAR-21-343: 1 U01 CA268810-01A1: NIH Intramural / Extramural Collaborative Research Polygenic Risk Stratification Combined with mpMRI to Identify Clinically Relevant Prostate Cancer Adam Kibel, MD, Chair Dept of Urology, Harvard Medical School
10:40 a.m. - 10:50 a.m.	Q&A
10:50 a.m. – 11:10 a.m.	Cycle #1 Funded Sites: Presentation on the current status of their projects and potential future collaborations considering Cycle #2 additions.
10:50 a.m. – 11:00 a.m.	Michigan-VUMC Biomarker Characterization Center Arul Chinnaiyan, MD, PhD, University of Michigan Jeffrey Tosoian, MD, MPH, Vanderbilt University Medical Center
11:00 a.m. – 11:10 a.m.	Virginia-UCLA-Toronto Biomarker Characterization Center Oliver John Semmes, PhD, Eastern Virginia Medical School Paul Boutros, PhD, University of California, Los Angeles Thomas Kislinger, PhD, University of Toronto
11:10 a.m. – 11:30 a.m.	Cycle #2 Funded Sites: Presentation on the current statue of their projects and potential future collaborations considering Cycle #2 additions.
11:10 a.m. – 11:20 a.m.	Prostate Cancer Biomarker and Imaging Validation Alliance: Emory University, University of Alabama Birmingham, and University of Texas Southwestern Martin Sanda, MD, Emory University
11:20 a.m. – 11:30 a.m.	BCC for Prostate Cancer: Discovery and Translation of Biomarkers for Clinical Unmet Needs Dan Chan, PhD, Johns Hopkins Hui Zhang, PhD, Johns Hopkins University School of Medicine
11:30 a.m. – 12:00 p.m.	Q/A
12:00 p.m. – 12:10 p.m.	Update and Discussion on P-MRI Study John Wei, MD, University of Michigan (tentative) Yingye Zheng, PhD, Fred Hutchinson Cancer Center Jackie Dahlgren, BS, Fred Hutchinson Cancer Center Guillermo Marquez, PhD, National Cancer Institute Phase 1 Study Phase 2 Study Next Steps
12:10 p.m. – 12:20 p.m.	Update and Discussion on Prostate Clinical Utility (PCU) Trial Lead Discussants: Jeffrey Tosoian, MD, Vanderbilt University Medical Center Michael Liss, MD, The University of Texas Health Science Center at San Antonio Next Steps
12:20 p.m. – 12:30 p.m.	Break
12:30 p.m. – 1:00 p.m.	Discussion on Potential NEW Collaborative Research Efforts (All will participate)

**NOTE: The newly funded sites will be giving longer presentations during the main part of the conference. The newly funded site presentations herein included are designed to provide more detailed information of interest and specific to the GU Collaborative Group as a whole. There will be ample time for questions and discussion throughout the dedicated EDRN GU Collaborative Group Meeting.